Takano et al. analyzed CD44 variant expression in thyroid tumors using reverse transcription-polymerase chain reaction (RT-PCR), and their findings revealed increased expression of CD44 variants in most FTC, particularly in follicular carcinomas, poorly differentiated PTC, and some FAs. The gene discussed is CD44; the disease is thyroid tumor.